Clinical trial
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
NCT00389441 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00389441 |
|---|---|
| Title | Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer |
| Official title | A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Neoplasms |
| Intervention type | Drug |
| Interventions | AG-013736 |
| Enrollment | 52 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Oct 18, 2006 |
| Last update posted | Nov 25, 2013 |
| Countries | Canada, China, Czechia, India, Italy, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: